Home › Amyotrophic Lateral Sclerosis › NCT05137665

Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At Home Measures

Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At - Home Measures

Who can join

Ages 18 and older · All sexes · Healthy volunteers welcome

ALS Participants:

1. Age 18 or older.
2. A diagnosis of ALS in accordance with Gold Coast criteria.
3. Full Vital Capacity (FVC) of ≥30% or at the discretion of the Principal Investigator for the participant's predicted value for gender, height, and age at the time of screening.
4. Ability to provide informed consent and understand the purpose and risks of the study.
5. Ability to comply with study procedures and assessments, in the opinion of the Principal Investigator.

Healthy Control Participants:

1. Age 18 or older.
2. No history of neurological disease, in the opinion of the Principal Investigator.
3. No known ALS- associated genetic mutations at the time of consent.
4. Ability to provide informed consent and understand the purpose and risks of the study.
5. Ability to comply with study procedures and assessments, in the opinion of the Principal Investigator.

About the study

The goal of the study is to generate a biorepository of longitudinal biofluids-blood (plasma and serum), cerebral spinal fluid (CSF) and urine linked to genetics and longitudinal clinical information that are made available to the research community. To accomplish these goals, we will enroll 800 Amyotrophic Lateral Sclerosis (ALS) patients and 200 healthy controls from sites globally, over a 5 year time frame. Additionally, speech and motor function and spirometry measures will be collected bi-weekly in a subset of participants. ALS participants will be asked to come to the clinic for 5 study visits approximately every 4 months. Healthy participants will be coming for 2 study visits with a 12-month interval between visits. These samples and clinical information will be stored in a de-identified manner and made available for investigators to use in future research studies.

Sponsor: Target ALS Foundation, Inc. · Participants: 1,000 · Started: Jun 1, 2021

Contact the study team

• Laura Dugom, MPH · Phone: 919-440-2073
• Robert Bowser, PhD · Phone: 602-406-8989

Official record on ClinicalTrials.gov — NCT05137665

Locations in the U.S.

Conditions

• Amyotrophic Lateral Sclerosis
• Movement Disorders
• ALS and Motor Neuron Disease

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.